A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 10 Jan 2012 Actual end date (1 Apr 2011) added as reported by ClinicalTrials.gov.
- 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.